Mereo BioPharma
23
0
2
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
30.4%
7 terminated/withdrawn out of 23 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
93%
13 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
Setrusumab vs Placebo for Osteogenesis Imperfecta
Role: collaborator
Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
Role: collaborator
EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
Role: collaborator
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
Role: lead
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency
Role: collaborator
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Role: collaborator
An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
Role: collaborator
A 6 Month Safety Extension Study of MBGS205
Role: lead
Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation
Role: lead
COVID-19 Study of Safety and Tolerability of Alvelestat
Role: collaborator
Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)
Role: collaborator
Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density
Role: collaborator
Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
Role: lead
Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease
Role: collaborator
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
Role: lead
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
Role: lead
A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis
Role: lead
Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery
Role: lead
BGS649 Monotherapy in Moderate to Severe Endometriosis Patients
Role: lead
Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men
Role: lead